news
Press release
 
September 13, 2013
Corindus Vascular Robotics Wins Mass Technology Leadership Council’s Award for Innovative Technology of the Year – Robotics

BOSTON, MA, September 13, 2013Corindus Vascular Robotics, a leading developer of precision vascular robotics, won the Massachusetts Technology Leadership Council’s Award for the 2013 Innovative Technology of the Year - Robotics last night at the Council’s 16th annual Awards Gala.

More than 700 senior executives were present at the Westin Waterfront for Boston’s premier annual tech awards event that showcases and celebrates the depth and breadth of the state’s vibrant technology ecosystem.

“We are honored to award Corindus with the 2013 Innovative Technology of the Year for Robotics,” said Tom Hopcroft, President and CEO of MassTLC. “Corindus’ leadership is a shining example of what it takes to keep the Commonwealth’s tech sector growing and thriving. It’s our pleasure to recognize and encourage such excellence. Congratulations to Corindus and the strong team behind their success.”

“Using robotics to set new standards of safety, precision and accuracy will greatly benefit patients of medical procedures, such as angioplasties,” said David Handler, president and CEO of Corindus Vascular Robotics. “We are working diligently every day to deliver a future where better outcomes in healthcare go hand-in-hand with innovation and are proud to have our robotics recognized by MassTLC as we continue with our mission.”

The first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties, Corindus’ CorPath 200 System is utilized to open blockages within arteries and restore blood flow in patients with coronary artery disease. During a CorPath angioplasty procedure, the interventional cardiologist sits in a radiation shielded interventional cockpit, where he is able to advance stents and guidewires via a joystick with millimeter by millimeter robotic precision. The CorPath enables precise measurement of the anatomy, which could potentially lead to better stent placements and improved clinical outcomes.

The 2013 MassTLC Leadership Awards program platinum sponsors are Cisco, Greenberg Traurig, Microsoft, pwc, Silicon Valley Bank and gold sponsors are Aericon, The Boston Globe, CA Technologies, KSquare Law, PTC, Raytheon and Sonus.

See all the 2013 winners at www.masstlc.org

About The Mass Technology Leadership Council, Inc.

The Mass Technology Leadership Council (MassTLC) is the region’s leading technology association and the premier network for tech executives, entrepreneurs, investors and policy leaders. MassTLC’s purpose is to accelerate innovation by connecting people from across the technology landscape, providing access to industry-leading content and ideas and offering a platform for visibility for member companies and their interests.

For more information on MassTLC visit www.masstlc.org

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window